National Kidney Foundation Innovation Fund Invests in Biohope

The National Kidney Foundation’s Innovation Fund has invested in Biohope, a biotechnology company focused on personalized medicine in kidney transplantation. Their flagship technology, Immunobiogram®, aims to tailor immunosuppressive therapy for kidney transplant recipients, addressing the challenges of current treatment methodologies that often rely on trial-and-error adjustments. This investment will help Biohope in clinical validation studies and seeking U.S. regulatory approval.